Printer Friendly

BRISTOL-MYERS SQUIBB, STERLING WINTHROP AND ELF SANOFI FINALIZE CARDIOVASCULAR DEVELOPMENT AGREEMENT

 PRINCETON, N.J. and NEW YORK, Aug. 2 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY), Sterling Winthrop, Inc., and its alliance partner, Elf Sanofi, announced today the signing of final agreements for a cooperative development and commercialization effort involving two promising cardiovascular compounds. Preliminary agreements were announced June 1.
 The worldwide strategic cooperative effort involves the joint development and commercialization of an Elf Sanofi angiotensin II receptor antagonist for the treatment of hypertension, and possibly other cardiovascular disorders; and clopidogrel, a novel antithrombotic agent for potential prevention of heart attack, stroke and peripheral arterial disease, which is currently being developed by the Elf Sanofi/Sterling Winthrop alliance.
 The angiotensin II receptor is in Phase II clinical trials in Europe and entering Phase II trials in the United States. It is expected to offer an advantage over several types of drugs now available for treating hypertension. Clopidogrel, an antithrombotic agent, is in Phase III clinical trials worldwide. Potential indications include prevention of secondary myocardial infarction, stroke and peripheral arterial disease.
 Development activities for the two products will be shared by the companies. Sterling Winthrop Pharmaceuticals Research Division and Sanofi Research will continue to lead development efforts for clopidogrel and the Bristol-Myers Squibb Pharmaceutical Research Institute will lead development efforts for the angiotensin II receptor antagonist. Upon regulatory approval, marketing for each country will be handled on a country by country basis, and may include co-marketing, co-promotion and joint venture entity marketing.
 Bristol-Myers Squibb is a research-based, diversified health care company whose principal businesses are pharmaceuticals, consumer products, nutritionals, and medical devices. It is among the world's leading makers of cardiovascular, anticancer, anti-infective, central nervous system and dermatological drug therapies, diagnostic agents and non-prescription medicines.
 -0- 8/2/93
 /CONTACT: Peggy Ballman of Bristol-Myers Squibb, 609-252-5323, or Terry G. Kelly of Sterling Winthrop, Inc. 212-907-3009/
 (BMY)


CO: Bristol-Myers Squibb Company; Sterling Winthrop Inc.; Elf Sanofi ST: New Jersey, New York IN: MTC SU:

PS-SM -- NY023 -- 8256 08/02/93 10:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 2, 1993
Words:329
Previous Article:ADVANCED COMMUNICATIONS SOFTWARE INTRODUCED FOR NEWTON;EX MACHINA DEBUTS POCKETCALL TERMINAL PROGRAM AND NOTIFY! WIRELESS MESSAGING TO NEWTON
Next Article:FUND AMERICA INVESTORS CORP. II 1993-C CLASS F-1 & B 'AAA' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters